AI Stock Monitor
AMGN - Amgen
Amgen is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Biotechnology · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NASDAQ · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score
75
/100
Price History
AMGN chart
AI-Assisted Chart Analysis
Amgen technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Constructive uptrend: the latest level is above the 50-period average and the 50-period average is above the 200-period average.
RSI is 62, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 336.79. A break below 272.98 invalidates the near-term support setup.
The first resistance/watch zone is 439.33. A confirmed break above 439.33 supports continuation.
Annualized realized volatility is +55.4%. Maximum lookback drawdown is -24.5%, from a high-water mark of 287.29 to 216.93.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported AMGN at 406.04 USD; the latest daily move was nearly unchanged at -0.01%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified -0.01% daily move is current market context for Amgen.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The current evidence-grounded AI read is neutral.
- Evidence: While the stock has reacted positively to this news, the sustainability of this momentum will depend on the company's ability to translate these clinical wins into commercial execution and regulatory approvals.
- Uncertainty: Uncertainty remains regarding the broader competitive landscape in autoimmune diseases, where other large-cap biopharma players are also aggressively pursuing market share.
- Watch: Investors should monitor upcoming regulatory filings and any management commentary regarding the commercialization strategy for dazodalibep to confirm the timeline for revenue contribution.
Key Risks
- Clinical success does not guarantee regulatory approval; any unforeseen safety signals or efficacy questions during the FDA review process for dazodalibep could reverse recent gains.
- The biopharma sector faces persistent pricing and regulatory scrutiny, which could impact the long-term profitability of new drug launches regardless of clinical efficacy.
- Execution risk remains in the commercial rollout of new assets, as Amgen must effectively compete against established therapies and potentially lower-cost biosimilar alternatives in the autoimmune space.
- If the company fails to meet market expectations for revenue growth in its core legacy portfolio, the positive sentiment generated by pipeline wins may be insufficient to maintain current valuation multiples.
Upcoming Catalysts
- Formal regulatory filings for dazodalibep will be the next critical milestone, providing clarity on the expected timeline for market entry and potential peak sales.
- Upcoming earnings reports will be essential to assess whether the positive clinical momentum is translating into improved operating margins and cash flow generation.
- Management updates on the commercial strategy for UPLIZNA and other key growth drivers will provide insight into the company's ability to sustain top-line growth in a competitive environment.
- Continued analyst coverage and potential further price target adjustments following the Phase 3 data release will likely influence short-term institutional sentiment and trading volume.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceReportedWinners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance · Published 2026-09-25 00:01:34Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedUPLIZNA Market Poised for Growth Through 2034 as Expanding Indications and Rising Demand Drive Sales Opportunities · Published 2026-09-25 00:01:34Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedAmgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease · Published 2026-09-25 00:01:34Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedAmgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease - Yahoo Finance · Published 2026-09-25 00:01:34Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedAmgen price target raised by Jefferies to $410 after positive Sjögren's data - ca.finance.yahoo.com · Published 2026-09-25 00:01:34Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.